PGY-2 Internal Medicine Resident @mhmedres @cwru | 🇮🇩 | Clinical Trials @Oxford_NDPH
Cleveland, OH
Joined April 2022
- Tweets166
- Following393
- Followers401
- Likes1.2K
Daniel Martin Simadibrata, MD retweeted
"Shifts in use of #GERD surgical procedures underscore advancements in procedures and evolving patient preferences," says @DM_Simadibrata of @MHMedRes at #DDW2025.
To get the full scoop, click here: ow.ly/kJg850VNiTQ
Daniel Martin Simadibrata, MD retweeted
✅Diagnostic accuracy of #GastroesophagealRefluxDisease questionnaire for gastroesophageal reflux disease: A systematic review and meta-analysis🔥🔥🔥🔥🔥
👉 onlinelibrary.wiley.com/doi/…
✔️xitter.cf/DM_Simadibrata/status/…
@ANMSociety @esnm_eu
#GITwitter #MedTwitter #ScienceTwitter
🔥 off the press in @NGMJournal (onlinelibrary.wiley.com/doi/…)
How accurate is the Gastroesophageal Reflux Disease Questionnaire (GerdQ) for diagnosing GERD?
Our meta-analysis showed that GerdQ had moderate sensitivity and specificity for GERD diagnosis
#GITwitter #GERD #MedTwitter
Daniel Martin Simadibrata, MD retweeted
COVID-19 Pandemic is Associated With Increased Prevalence of GERD and Decreased GERD-related Quality of Life: Analysis From 9800 Participants in the Indonesian GERD-Q Study..@Medicine_UI @univ_indonesia @WorldGastroOrg
Journal of Clinical Gastroenterology journals.lww.com/jcge/abstra…
Daniel Martin Simadibrata, MD retweeted
Landmark study on Violence Against Healthcare Workers‼️
Our study explored incidents of violence among 1504 healthcare workers in 79 countries to shed light on this global crisis 🌏
We have a long way to go in protecting our 🏥 workforce.
#SafetyFirst
Daniel Martin Simadibrata, MD retweeted
Bagi teman2 yg lg free malam sabtu.. Yuk join acara dari SinauYuk ttg writing and publishing in journal.. 😁😁😁 – at Kebayoran Lama, Indonesia
Daniel Martin Simadibrata, MD retweeted
How does the rise in antibiotic resistance to H. pylori treatment options affect management⁉️
Take the poll below 📊 and let us know‼️
@ACG_EBGI #MedTwitter #GITwitter #EBGI
Daniel Martin Simadibrata, MD retweeted
It’s ⏰ for #EBGI⭐️Case of the Week⭐️with @seanpattyp
📌Test your knowledge of the latest clinical guidelines & ground-breaking clinical research📄
📌Practice an evidence-based approach to common💩problems with quick refresher cases, perfect for a busy clinic day🩺
#GITwitter
Daniel Martin Simadibrata, MD retweeted
Delighted to finally get this paper over the line after working on it for so long. A huge collaborative effort. Thanks for all your help @DM_Simadibrata
(1/4) Happy to share a recently published study 🔥 off the press in JCC!
academic.oup.com/ecco-jcc/ar…
We utilized ePROMs data collected from the TrueColours-#IBD to develop an escalation of therapy or intervention calculator for #UlcerativeColitis patients
@OUH_research #GITwitter
Daniel Martin Simadibrata, MD retweeted
First time I experience the #Indonesian_cuisine ❤️ 🇮🇩
And let me tell you… Can’t wait to find a conference in Bali 🧳 ✈️ 🏝️
#Travel #Food #Amsterdam – at Amsterdam, The Netherlands
Daniel Martin Simadibrata, MD retweeted
Development of the Escalation of Therapy or Intervention (ETI) calculator for patients with ulcerative colitis using ePROMS dlvr.it/SqbX5m
Daniel Martin Simadibrata, MD retweeted
Delighted to share that our work on the development of an algorithmic tool to estimate the risk of the Escalation of Therapy or Intervention (ETI) for patients with Ulcerative Colitis using their electronic reports, was published by @OUPMedicine academic.oup.com/ecco-jcc/ar…
Daniel Martin Simadibrata, MD retweeted
A new opinion piece in @TheLancet by @MartinLandray, @RichardHaynes3, and Christina Reith responds to Sir James O'Shaughnessy's review into commercial clinical trials.
Read more 👉 bit.ly/3MXuKPG
ALT Purple liquid being dispensed into test tubes.
Daniel Martin Simadibrata, MD retweeted
FINALLY PUBLISHED
The first clinical trial conceived by our research institute, SATURATE.
I’m not personally involved in the conduct of the trial. But, I’m very elated to inform all of my twitter friends that the results may challenge our current paradigm of DS-TB therapy
Daniel Martin Simadibrata, MD retweeted
Vonoprazan is superior to PPI in first-line H. pylori eradication and erosive esophagitis but non-inferior in other gastric acid-related diseases.
Short-term safety is comparable in both treatment groups.
buff.ly/3jina6V
Daniel Martin Simadibrata, MD retweeted
New study finds strong association between educational level and premature mortality in Cuba, with substantial impact from #smoking
Read more 👉 bit.ly/3DUfkZ6
@TheLancetPH @OxfordMedSci
Daniel Martin Simadibrata, MD retweeted
This letter by the @AmCollegeGastro highlights the important findings of the recent NEJM study with its outcomes and major potential misinterpretations
#Screening saves lives!
👇🏽 – at Los Angeles, CA
ACG today reacted with a Letter to the Editor of @CNN on misleading story re: NEJM NordICC #Colonoscopy trial
CNN's coverage does a significant potential disservice to public health and fails to convey limitations of the analysis of the NordICC trial
>> bit.ly/ACG-to-CNN
Daniel Martin Simadibrata, MD retweeted
PCAB or #PPI for #Gastric-acid related diseases? Our latest #meta-analysis - ow.ly/k65R50KZV4F @JGH_latest @DM_Simadibrata
Daniel Martin Simadibrata, MD retweeted
Proud to have Ryan Reynolds at our endoscopy unit @nyulangone with @DrLaPook promoting the importance of colon cancer screening. Along with Rob McElhenney they show us why finding & removing polyps with #colonoscopy is potentially lifesaving. @VancityReynolds @RMcElhenney
I made a bet. I lost. But it still paid off. @LeadFromBehind @RMcElhenney @DrLaPook @NYULangone @RMcElhenney